NCT02042807View on ClinicalTrials.gov

To Evaluate the Effect of MCS® in Prostate Cancer Prevention

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

702

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Prostate Cancer
Interventions
DRUG

Placebo

DRUG

MCS®

Trial Locations (1)

Unknown

Department of Urology, National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Health Ever Bio-Tech Co., Ltd.

INDUSTRY

NCT02042807 - To Evaluate the Effect of MCS® in Prostate Cancer Prevention | Biotech Hunter | Biotech Hunter